5-Lipoxygenase in the Central Nervous System: Therapeutic Implications

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 15, 3 Issues, 2016

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

5-Lipoxygenase in the Central Nervous System: Therapeutic Implications

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 1(2): 115-121.

Author(s): Hari Manev and Tolga Uz.

Affiliation: Psychiatric Institute,University of Illinois at Chicago, 1601 West Taylor Street, M / C 912, Room238, Chicago, Illinois 60612, USA


5-Lipoxygenase (5-LOX) is a protein with catalytic activity that is essential for transforming arachidonic acid into leukotrienes and that has the ability to bind and possibly affect the function of a number of cellular proteins, including cytoskeletal proteins. A limited number of clinically-used drugs target the 5-LOX pathway, they are either 5-LOX inhibitors or antagonists of leukotriene receptors and are primarily used for the treatment of asthma. 5-LOX is also expressed and enzymatically active in various compartments of the mammalian brain, including central nervous system (CNS) neurons. However, insufficient information is available on the extent to which 5-LOX-related drugs cross the blood-brain barrier. Research into the CNS 5-LOX pathway indicates that 5-LOX may participate in a number of brain pathologies, including developmental neurometabolic diseases, stroke, seizures, Alzheimers disease, aging-associated neurodegeneration, prion disease, multiple sclerosis, and brain tumors. Physiologically, 5-LOX appears to be involved in neurogenesis. The expression of 5-LOX is affected by hormones and appears to be subject to epigenetic regulation via alterations in DNA methylation in the region of the 5-LOX promoter. In this review, we propose that a novel 5-LOX drug therapy could be targeted not only to 5-LOX enzymatic activity and leukotrienes, but also toward modifying 5-LOX expression and the possibility of interfering with non-enzymatic actions of 5-LOX proteins. It is suggested that a new 5- LOX pharmacopoeia, which would be effective in the CNS would significantly advance research on the role of 5-LOX in the brain.


5-Lipoxygenase, 5-LOX PATHWAY, CNS PATHOLOGY, Neurometabolic Diseases, Alzheimers Disease, Prion Disease.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 1
Issue Number: 2
First Page: 115
Last Page: 121
Page Count: 7
DOI: 10.2174/1568014023355980
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science